---
document_datetime: 2024-09-23 16:12:00
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/orladeyo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: orladeyo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.873616
conversion_datetime: 2025-12-23 02:35:34.323506
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Orladeyo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                  |
|----------------------|------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10930 /202312  | Periodic Safety Update EU Single assessment - berotralstat | 25/07/2024                          | 19/09/2024                                  | SmPC and PL                      | Please refer to Orladeyo- EMEA/H/C/PSUSA/00010930/202312 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| II/0017/G            | This was an application for a group of variations.         | 27/06/2024                          | 26/07/2024                                  | SmPC and PL                      | The MAH has submitted the results from Study BCX7353- 119 (Study 119), 'A Phase 1 drug-drug interaction study to                                                         |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| A grouped application comprised variations, as follows: C.I.4: Update of section 4.4 and order to add a warning on QT prolongation remove the recommendation for adverse events with concomitant BCRP inhibitors based on final safety drug-drug interaction study BCX7353-119, to update the effects of cyclosporine Study BCX7353-119 is a phase interaction study to evaluate the cyclosporine on the pharmacokinetics in healthy subjects. C.I.13: Submission of the final and 3 of study BCX7353-301; this randomized, double-blind, placebo-controlled, parallel-group study to evaluate safety of two dose levels of BCX7353 treatment for the suppression of with hereditary angioedema. In addition, the MAH took the opportunity additional wording for patients kidney function in the Package introduce minor editorial changes previous guidance. C.I.4 - Change(s) in the SPC, Labelling new quality, preclinical, clinical   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                         |            |     | SmPC new text   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| IB/0019   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                   | 20/03/2024 | n/a |                 |
| IB/0015/G | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                  | 09/11/2023 | n/a |                 |
| IA/0016   | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                        | 08/11/2023 | n/a |                 |
| IB/0014   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                         | 20/10/2023 | n/a |                 |
| IB/0013/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - | 07/08/2023 | n/a |                 |

<div style=\"page-break-after: always\"></div>

|                     | Tightening of in-process limits B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10930 /202212 | Periodic Safety Update EU Single assessment - berotralstat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 06/07/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10930 /202206 | Periodic Safety Update EU Single assessment - berotralstat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/01/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0011             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/12/2022 | 09/10/2023 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0006             | Update of sections 4.4 and 4.5 of the SmPC in order to remove the warning for women of childbearing potential and amend drug-drug interaction information with desogestrel based on final results from study BCX7353-111; this is a phase 1 drug interaction study to evaluate the effects of berotralstat on the pharmacokinetics of a combination oral contraceptive, desogestrel with ethinyl estradiol; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 01/09/2022 | 09/10/2023 | SmPC and PL | SmPC new text Section 4.4 Section 4.5 CYP2C9 substrates Berotralstat is a weak inhibitor of CYP2C9 increasing the Cmax and AUC of tolbutamide by 19% and 73%, respectively. No dose adjustment is recommended for concomitant use of medicines that are predominantly metabolised by CYP2C9 (e.g. tolbutamide) (see section 5.2). The effect of berotralstat on the CYP2C9 conversion of desogestrel to etonogestrel (active metabolite) was negligible. No dose adjustment is recommended for concomitant use of desogestrel. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                        |            |     | Product Characteristics and PL changes. Package leaflet change Section 2 Other medicines and Orladeyo The following changes were made Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Particularly, tell your doctor before taking Orladeyo if you are using: â€¢ oral contraceptives, medicines used for birth control   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                             | 08/08/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0008             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 26/07/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10930 /202112 | Periodic Safety Update EU Single assessment - berotralstat                                                                                                             | 07/07/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                |
| IA/0007             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                       | 31/03/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0005             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                   | 22/02/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10930         | Periodic Safety Update EU Single assessment -                                                                                                                          | 13/01/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| /202106   | berotralstat                                                                                                                                                                                                             |            |            |             |               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------|
| IAIN/0002 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - batch control/testing | 03/08/2021 | n/a        |             | Not including |
| IAIN/0001 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                               | 08/06/2021 | 01/07/2022 | SmPC and PL |               |